GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InfuSystems Holdings Inc (AMEX:INFU) » Definitions » Peter Lynch Fair Value

InfuSystems Holdings (InfuSystems Holdings) Peter Lynch Fair Value : $0.63 (As of May. 11, 2024)


View and export this data going back to 1992. Start your Free Trial

What is InfuSystems Holdings Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, InfuSystems Holdings's PEG is 1. InfuSystems Holdings's 5-Year TTM EBITDA Growth Rate is 19.15. InfuSystems Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.03. Therefore, the Peter Lynch Fair Value for today is $0.63.

As of today (2024-05-11), InfuSystems Holdings's share price is $7.28. InfuSystems Holdings's Peter Lynch fair value is $0.63. Therefore, InfuSystems Holdings's Price to Peter Lynch Fair Value Ratio for today is 11.52.


The historical rank and industry rank for InfuSystems Holdings's Peter Lynch Fair Value or its related term are showing as below:

INFU' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.94   Med: 9.73   Max: 16.73
Current: 11.56


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of InfuSystems Holdings was 16.73. The lowest was 0.94. And the median was 9.73.


INFU's Price-to-Peter-Lynch-Fair-Value is ranked worse than
98.42% of 190 companies
in the Medical Devices & Instruments industry
Industry Median: 1.735 vs INFU: 11.56

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


InfuSystems Holdings Peter Lynch Fair Value Historical Data

The historical data trend for InfuSystems Holdings's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InfuSystems Holdings Peter Lynch Fair Value Chart

InfuSystems Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 20.00 1.75 - 0.63

InfuSystems Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.75 1.00 0.63

Competitive Comparison of InfuSystems Holdings's Peter Lynch Fair Value

For the Medical Instruments & Supplies subindustry, InfuSystems Holdings's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InfuSystems Holdings's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InfuSystems Holdings's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where InfuSystems Holdings's Price-to-Peter-Lynch-Fair-Value falls into.



InfuSystems Holdings Peter Lynch Fair Value Calculation

InfuSystems Holdings's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 19.15 *0.033
=0.63

InfuSystems Holdings's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


InfuSystems Holdings  (AMEX:INFU) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 19.15 instead of 15 in this case.

InfuSystems Holdings's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=7.28/0.63
=11.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InfuSystems Holdings Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of InfuSystems Holdings's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


InfuSystems Holdings (InfuSystems Holdings) Business Description

Traded in Other Exchanges
Address
3851 West Hamlin Road, Rochester Hills, MI, USA, 48309
InfuSystems Holdings Inc is a United States based healthcare service provider. It offers Infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from the locations in the United States and Canada. The company provides products and services to hospitals, oncology practices and chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The segments of the company are Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) services, of which key revenue is derived from the ITS segment.
Executives
Jerod Funke officer: EVP-Chief HR Officer 3851 WEST HAMLIN RD, ROCHESTER HILLS MI 48309
R. Rimmy Malhotra director C/O COMMAND CENTER, INC., 3609 S WADSWORTH BLVD., SUITE 250, LAKEWOOD CO 80235
Gregg Owen Lehman director 309 HADDON COURT, FRANKLIN X1 37067
Richard Dilorio officer: Executive Vice President 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Barry G Steele officer: Executive VP and CFO 500 TOWN CENTER DR., SUITE 200, DEARBORN MI 48126
Carrie Lachance officer: Executive VP and COO 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Christopher R. Sansone director C/O SANSONE ADVISORS, LLC, 151 BODMAN PLACE, SUITE 100, RED BANK NJ 07701
Addam Chupa officer: Executive VP and CIO 3851 WEST HAMLIN ROAD, ROCHESTER HILLS MI 48309
Kevin Whitman officer: VP and Corporate Controller 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Thomas Mark Ruiz officer: VP of Sales and Marketing 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Boyd Ralph F Jr director
Paul Andrew Gendron director 740 BANDIT TRAIL, KELLER TX 76248
Jeannine Sheehan officer: Chief Administrative Officer 31700 RESEARCH PARK DRIVE, MADISON HEIGHTS MI 48071
Blueline Capital Partners Ii, L.p. director 3480 BUSKIRK AVENUE, SUITE 214, PLEASANT HILL CA 94523
Meridian Tsv Ii, Lp 10 percent owner 405 WEED STREET, NEW CANAAN CT 06840